December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
A 3-month Comparison of Efficacy and Safety of Brimonidine-tartrate 0.2% / Timolol 0.5% Fixed Combination (bid) With Timolol 0.5% (bid) or Brimonidine-tartrate 0.2% (tid)
Author Affiliations & Notes
  • ER Craven
    Glaucoma Consultants of Colorado Littleton CO
  • N Choplin
    Eye Care of San Diego San Diego CA
  • C Larsen
    Allergan Inc Irvine CA
  • M Olson
    Allergan Inc Irvine CA
  • S Whitcup
    Allergan Irvine CA
  • Footnotes
    Commercial Relationships    E.R. Craven, Allergan R; N. Choplin, None; C. Larsen, Allergan E; M. Olson, Allergan E; S. Whitcup, Allergan E.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 282. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      ER Craven, N Choplin, C Larsen, M Olson, S Whitcup; A 3-month Comparison of Efficacy and Safety of Brimonidine-tartrate 0.2% / Timolol 0.5% Fixed Combination (bid) With Timolol 0.5% (bid) or Brimonidine-tartrate 0.2% (tid) . Invest. Ophthalmol. Vis. Sci. 2002;43(13):282.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the IOP-lowering efficacy of fixed combination brimonidine 0.2%/timolol 0.5% BID (BrimTim) with timolol 0.5% BID or brimonidine 0.2% (ALPHAGAN®) TID. Methods: Data were pooled from 2 identical, randomized, double-masked, multi-center trials. Adult patients with glaucoma or OHT (IOP 22-34 mmHg) received 1 of the above 3 treatment regimens. IOP was measured at day 0, week 2, week 6, and month 3 at 8am, 10am, 3pm, and 5pm. Results:  

Mean baseline IOP was similar among the three groups. In subsequent visits, mean IOP was lower with BrimTim than with either brimonidine or timolol at all time points; these differences were statistically significant at 11 out of 12 time points (p< 0.018). Reduction in mean IOP from baseline at 10am (peak effect), month 3 was 7.6 mm Hg with BrimTim, compared to 5.5 mm Hg with brimonidine (p<0.001) and 5.6 mm Hg with timolol (p<0.001). BrimTim also achieved IOP below specified target pressures (<18 mm Hg, or ≷20% decrease from baseline) over 3 months in more patients than either timolol or brimonidine alone (p≤0.010). Most of the treatment-related adverse events in all three groups were ocular and mild. BrimTim was well tolerated with few systemic side effects. Conclusion: The brimonidine/timolol fixed combination was safe and provided IOP reduction superior to that provided by either timolol or brimonidine monotherapy. Study supported by Allergan, Inc.

Keywords:  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×